Fearing supply shortfall, EU wants to buy more COVID vaccines - EU sources

Clay Curtis
September 20, 2020

The CEO of Moderna, the first company to conduct large-scale human trials of a COVID-19 vaccine candidate in the USA, says the firm will likely have enough data to announce in November whether its novel coronavirus vaccine is sufficiently effective for broader use.

The Cambridge-based company embarked on Phase 3 of its study, dubbed COVE (Coronavirus Efficacy), in effort to test its prototype vaccine, and began administering doses to 30,000 Americans over the summer. Serum Institute of India (SII) and ICMR have partnered for clinical development of two global vaccine candidates - ChAdOx1-S, which is a non- replicating viral vector vaccine developed by University of Oxford/AstraZeneca. The trial will be initiated in the second half of October after the vaccine is manufactured by Serum Institute.

"The Health Minister must respond now or he may have to answer to the people later on why Malaysia is last in the queue for the vaccines", he said. The government of India conveyed its intent to be part of the Vaccine Pillar of the Access to Covid-19 Tools (ACT) Accelerator, which may be beneficial in providing access to the global vaccine candidates in advanced stages, for their further utilization in the country.

Express Explained is now on Telegram. "Phase I clinical trials along with parallel studies in hamsters and rhesus macaques have been completed and have revealed excellent safety of the candidate vaccine".

The two documents contain information about the criteria used for selecting trial participants, how they are being monitored and the evidence that will be used to assess whether the vaccine is effective.

Blake Shelton and Gwen Stefani's secret behind their ACM Awards duet
Apparently, the root of the conflict between the couple of almost five years is all the stress that came with their move. Another said: "You did NOT with this photoshopping!" Who knows, maybe 2021 will be their year!

The Sputnik V vaccine works on the "human adenoviral vector" technology, which modifies adenoviruses (that are responsible for causing illnesses like fevers, coughs, diarrhoea, etc in humans) so they do not replicate in the human body, and instead carry instructions to cells to produce spike protein of COVID-causing SARS-CoV-2 virus.

In its document, Moderna has said it expected to know about the effectiveness of its vaccine by December.

The remaining doses were promised to India, Bangladesh, China, Brazil, Indonesia, and Mexico, among other developing nations, the charity added.

The Commission has privately warned EU governments not to buy vaccines through COVAX, European officials have told Reuters, as the global procurement scheme could result in the EU having a small share of shots as its population is only 450 million of the world's almost 8 billion people.

With the fourth quarter fast approaching, it's do-or-die time for a group of drugmakers chasing the first approved vaccine for COVID-19.

Other reports by

Discuss This Article